Theoretically, so long as there is a sink-source for malaria, transmission could be sustained at very low level (even at sub-microscopic oscillation) and reintroduce malaria either as sporadic cases or as resurgent outbreak. Uncertainty or shortage in financing has typically limited the malaria control or elimination projects to go further beyond the "Pre-elimination phase". Since malaria is no longer a top scoring mortality in national statistics in South East Asia, the governments/stakeholders are less willing to allocate from the austerity budget. There are proven evidence of resurgences after cessation of intervention programs where over 90% of all resurgence events were attributed to the interruption of malaria control programmes. In Karen state Myanmar-Thailand border, multiple factors including a cascade of political, financial, and logistical fiascos have compounded on the ongoing malaria elimination activities. Deleterious impacts after military coup since 2021 February including cessation of foreign investment, humanitarian aids, Civil Dis-obedience Movement of government staff and resuming armed-conflicts have strained the nearly failed health infrastructure of the country to a collapse stage. Interruption of the National Malaria Control activities due to the health system failure and accelerating combats countrywide could inevitably lead to the overturn in recently achieved malaria pre-elimination status especially in Karen state.
The disruption in health services within Myanmar is already resulting in an increase in malaria. Supply of the first line antimalarial drug artemether-lumefantrine, and other essential malaria control interventions, has been interrupted. The study is proposed to evaluate the impact of Mass Drug Administration (MDA) in 3 villages in Karen state with consistently high incidence of P. vivax and spatially clustered within 5 km radius. This proposal outlines a study to assess the feasibility and the safety of tafenoquine MDA.

开始日期2024-10-01

申办/合作机构-

CTRI/2024/07/071492 / Not yet recruiting临床3期

A randomized, open-label, multi-center, interventional Phase 3 study of the efficacy and safety of tafenoquine compared to primaquine (both co-administered with chloroquine) for the radical cure (relapse prevention) of Plasmodium vivax (P. vivax) malaria in Indian participants (pediatric and adult population) - NIL

开始日期2024-09-02

申办/合作机构

GlaxoSmithKline Research & Development Ltd.

[+1]

NCT04704999 / Recruiting临床4期IIT

Optimizing the Dose of Tafenoquine for the Radical Cure of Plasmodium Vivax Malaria in Southeast Asia

Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the hypnozoite). Tafenoquine (an 8-aminoquinoline) has the substantial advantage of single dosing as compared to a 14-day course of primaquine to achieve radical cure. The recommended tafenoquine dose is 300 mg, which was shown to be significantly worse in radical curative efficacy to a total primaquine dose of 3.5 mg/kg in Southeast Asia. The cure rate of tafenoquine 300 mg in Southeast Asian study sites was only 74%. The comparator 3.5 mg/kg total primaquine dose is the standard and most commonly used dose globally, but in Southeast Asia and the Western Pacific, higher doses of primaquine are needed for radical cure. This study aims to determine the optimal dose of tafenoquine in Southeast Asia.

开始日期2024-07-22

申办/合作机构

University of Oxford

100 项与琥珀酸他非诺喹相关的临床结果

登录后查看更多信息

100 项与琥珀酸他非诺喹相关的转化医学

登录后查看更多信息

100 项与琥珀酸他非诺喹相关的专利（医药）

登录后查看更多信息

289

项与琥珀酸他非诺喹相关的文献（医药）

2024-10-01·JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Primaquine-5,6-Orthoquinone Is Directly Hemolytic to Older G6PD Deficient RBCs in a Humanized Mouse Model

Article

作者: Tekwani, Babu L ; Legenzov, Eric A ; Walker, Larry A ; Lamb, Derek R ; Dziewulska-Cronk, Karolina H ; Zimring, James C ; Reisz, Julie A ; Kao, Joseph P Y ; Issaian, Aaron ; Palha, Mitasha S ; Hay, Ariel M ; Nemkov, Travis ; Cendali, Francesca I ; D'Alessandro, Angelo ; Buehler, Paul W

Primaquine and Tafenoquine are the only approved drugs that can achieve a radical cure for Plasmodium vivax malaria but are contraindicated in patients who are deficient in glucose 6-phosphate dehydrogenase (G6PDd) due to risk of severe hemolysis from reactive oxygen species generated by redox cycling of drug metabolites. 5-hydroxyprimaquine and its quinoneimine cause robust redox cycling in red blood cells (RBCs) but are so labile as to not be detected in blood or urine. Rather, the quinoneimine is rapidly converted into primaquine-5,6-orthoquinone (5,6-POQ) that is then excreted in the urine. The extent to which 5,6-POQ contributes to hemolysis remains unclear, although some have suggested that it is a minor toxin that should be used predominantly as a surrogate to infer levels of 5-hydroxyprimaquine. In this report, we describe a novel humanized mouse model of the G6PD Mediterranean variant (hG6PD_Med-) that recapitulates the human biology of RBC age-dependent enzyme decay, as well as an isogenic matched control mouse with human nondeficient G6PD hG6PD_ND In vitro challenge of RBCs with 5,6-POQ causes increased generation of superoxide and methemoglobin. Infusion of treated RBCs shows that 5,6-POQ selectively causes in vivo clearance of older hG6PD_Med- RBCs. These findings support the hypothesis that 5,6-POQ directly induces hemolysis and challenges the notion that 5,6-POQ is an inactive metabolic waste product. Indeed, given the extreme lability of 5-hydroxyprimaquine and the relative stability of 5,6-POQ, these data raise the possibility that 5,6-POQ is a major hemolytic primaquine metabolite in vivo. SIGNIFICANCE STATEMENT: These findings demonstrate that 5,6-POQ, which has been considered an inert waste product of primaquine metabolism, directly induces ROS that cause clearance of older G6PDd RBCs. As 5,6-POQ is relatively stable compared with other active primaquine metabolites, these data support the hypothesis that 5,6-POQ is a major toxin in primaquine induced hemolysis. The findings herein also establish a new model of G6PDd and provide the first direct evidence, to our knowledge, that young G6PDd RBCs are resistant to primaquine-induced hemolysis.

2024-07-25·JOURNAL OF INFECTIOUS DISEASES

A Planned Trial to Evaluate the Safety and Efficacy of Tafenoquine + Atovaquone/Azithromycin in Hospitalized Patients With Babesiosis

Article

作者: Dow, Geoffrey S ; Smith, Bryan

2024-07-25·JOURNAL OF INFECTIOUS DISEASES

Reply to Dow and Smith

Article

作者: Wormser, Gary P ; Ben Mamoun, Choukri

项与琥珀酸他非诺喹相关的新闻（医药）

2024-09-06

·GlobeNewswire-Health Care

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

WASHINGTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced private placement, priced at-the-market under Nasdaq rules, of an aggregate of 2,898,551 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 2,898,551 shares of common stock and short-term series B warrants to purchase up to 2,898,551 shares of common stock at a purchase price of $1.38 per share (or per common stock equivalent in lieu thereof) and accompanying warrants. The series A warrants and short-term series B warrants have an exercise price of $1.38 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants (the “Stockholder Approval”). The series A warrants will expire five years from the Stockholder Approval and the short-term series B warrants will expire eighteen months from the Stockholder Approval. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. The gross proceeds to 60P from the offering are approximately $4 million, before deducting the placement agent’s fees and other offering expenses payable by 60P, and excluding the proceeds, if any, from the exercise of the warrants. 60P intends to use the net proceeds from the offering for working capital, general operations, commercialization activities related to Arakoda, and the Company’s research and development program. The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities described above, including the shares of common stock underlying the warrants, may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the current view about future events, and include, among others, statements related to the receipt of Stockholder Approval and the intended use of proceeds from the private placement. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: market and other conditions; there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain U.S. Food and Drug Administration (FDA) approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except is required by law. Investor Contact: Patrick Gaynespatrickgaynes@60degreespharma.com(310) 989-5666

上市批准

2024-09-04

·GlobeNewswire-Health Care

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

WASHINGTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,898,551 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 2,898,551 shares of common stock and short-term series B warrants to purchase up to 2,898,551 shares of common stock at a purchase price of $1.38 per share (or per common stock equivalent in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $1.38 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants (the “Stockholder Approval”). The series A warrants will expire five years from the Stockholder Approval and the short-term series B warrants will expire eighteen months from the Stockholder Approval. The closing of the offering is expected to occur on or about September 5, 2024, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement. The gross proceeds to 60P from the offering are expected to be approximately $4 million, before deducting the placement agent’s fees and other offering expenses payable by 60P, and excluding the proceeds, if any, from the exercise of the warrants. 60P intends to use the net proceeds from the offering for working capital, general operations, commercialization activities related to Arakoda, and the Company’s research and development program. The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities described above, including the shares of common stock underlying the warrants, may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement, the Company has agreed to file a resale registration statement covering the securities described above. This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the current view about future events, and include, among others, statements related to the completion of the private placement, the satisfaction of customary closing conditions related to the private placement, the receipt of Stockholder Approval and the intended use of proceeds from the private placement. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: market and other conditions; there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain U.S. Food and Drug Administration (FDA) approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except is required by law. Investor Contact: Patrick Gaynespatrickgaynes@60degreespharma.com(310) 989-5666

上市批准

2024-08-28

·GlobeNewswire-Health Care

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

WASHINGTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on August 26, 2024 it received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The Company had been notified by Nasdaq on February 27, 2024 that it was not in compliance with the Minimum Bid Price Requirement because its common stock had failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. In order to regain compliance with the Minimum Bid Price Requirement, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved during the period between August 12, 2024 and August 23, 2024. The Company’s closing price was $1.81 on August 23, 2024. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. Cautionary Note Regarding Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain U.S. Food and Drug Administration (FDA) approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Contact: Patrick Gaynespatrickgaynes@60degreespharma.com(310) 989-5666

上市批准

100 项与琥珀酸他非诺喹相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10670	琥珀酸他非诺喹	P01BA07	DB06608

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
疟疾	美国	60 Degrees Pharmaceuticals, Inc.	2018-08-08
间日疟原虫感染	美国	Glaxosmithkline Intellectual Property Development Ltd.	2018-07-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
溶血	临床3期	巴西	GSK Plc	2015-04-30
溶血	临床3期	哥伦比亚	GSK Plc	2015-04-30
溶血	临床3期	埃塞俄比亚	GSK Plc	2015-04-30
溶血	临床3期	秘鲁	GSK Plc	2015-04-30
溶血	临床3期	泰国	GSK Plc	2015-04-30
溶血	临床3期	越南	GSK Plc	2015-04-30
巴贝虫病	临床2期	美国	60 Pharmaceuticals LLC	2024-06-17
新型冠状病毒感染	临床2期	美国	60 Pharmaceuticals LLC	2021-02-19
恶性疟	临床2期	-	Smithkline Beecham	2000-05-01
念珠菌病	临床2期	美国	60 Pharmaceuticals LLC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACTRN12620000995976 (Australian and New Zealand Clinical Trials Registry, Pubmed \| Clin Infect Dis)	临床1期	疟疾 \| 感染 glucose 6-phosphate dehydrogenase (G6PD)	12	Tafenoquine 200 mg	製鏇糧範築願憲鬱鹹壓(鹽鏇窪構廠夢憲遞廠糧) = 遞鹽艱觸選製衊憲選網淵廠鏇蓋鑰網壓獵醖繭 (鑰窪製艱簾壓艱鏇鏇網 )	积极	2023-06-08
				Tafenoquine 300 mg	製鏇糧範築願憲鬱鹹壓(鹽鏇窪構廠夢憲遞廠糧) = 顧淵積獵淵觸積顧襯獵淵廠鏇蓋鑰網壓獵醖繭 (鑰窪製艱簾壓艱鏇鏇網 )
NCT02802501 (200894, Pubmed)	临床3期	间日疟原虫感染	150	Dihydroartemisinin-piperaquine alone	簾夢鬱衊齋鹽鹽蓋獵積(淵網壓蓋觸窪膚簾構鹹) = 夢艱遞遞壓廠構構範襯鬱夢鹹艱鹽遞醖夢襯醖 (淵遞鹹範衊製願壓積簾, 4 ~ 22)	不佳	2023-05-23
				Dihydroartemisinin-piperaquine plus tafenoquine	簾夢鬱衊齋鹽鹽蓋獵積(淵網壓蓋觸窪膚簾構鹹) = 製願範積蓋獵築艱鹹襯鬱夢鹹艱鹽遞醖夢襯醖 (淵遞鹹範衊製願壓積簾, 11 ~ 34)
NCT05788094 (Pubmed)	临床4期	间日疟原虫感染	-	Tafenoquine 5 mg/kg	淵構獵夢艱簾廠夢製齋(範鏇顧範襯衊獵齋願鏇) = 窪簾遞憲網艱顧餘築願鹽壓衊艱衊觸壓鬱廠範 (衊衊願範齋廠範簾網艱 )	-	2022-12-06
				Tafenoquine 7.5 mg/kg	淵構獵夢艱簾廠夢製齋(範鏇顧範襯衊獵齋願鏇) = 憲構鬱獵醖衊製蓋範夢鹽壓衊艱衊觸壓鬱廠範 (衊衊願範齋廠範簾網艱 )
NCT02563496 (TEACH \| TAF113577, Corporate Publications) 人工标引	临床2期	间日疟原虫感染	60	Tafenoquine Succinate	夢鏇艱憲醖艱窪範鑰網(廠蓋觸製醖鬱淵鏇範鹽) = 簾艱遞夢鏇餘壓夢積顧鑰繭鬱積鏇窪憲繭簾鑰 (顧鏇夢願艱膚夢憲餘窪 ) 更多	积极	2020-11-19
NCT02563496 (CTgov)	临床2期	间日疟原虫感染	60	Tafenoquine+Chloroquine (Tafenoquine 100 mg)	廠蓋觸淵鹹膚積艱構餘(獵膚願鹽鬱醖選願糧壓) = 範醖製願鹹鏇繭蓋夢淵蓋艱糧壓製膚鏇顧獵顧 (廠繭糧餘齋餘網艱蓋簾, 憲範憲醖淵糧範膚觸醖 ~ 製築憲鹹糧構廠獵窪鑰) 更多	-	2020-11-02
				Tafenoquine+Chloroquine (Tafenoquine 150 mg)	廠蓋觸淵鹹膚積艱構餘(獵膚願鹽鬱醖選願糧壓) = 醖選選獵簾窪醖製蓋願蓋艱糧壓製膚鏇顧獵顧 (廠繭糧餘齋餘網艱蓋簾, 範衊蓋構構繭網壓衊構 ~ 製夢襯餘壓膚膚鏇齋廠) 更多
NCT02802501 (200894, CTgov)	临床3期	间日疟原虫感染	150	DHA-PQP (DHA-PQP Only)	獵襯衊衊願觸蓋夢夢遞(網網憲壓簾鏇鏇願構鏇) = 鬱餘繭遞廠獵淵積窪壓夢齋網簾網鹽製簾範簾 (憲獵襯憲獵構網醖窪獵, 膚顧鏇簾窪鑰衊顧憲襯 ~ 膚積簾襯願蓋選襯艱廠) 更多	-	2020-07-24
				Tafenoquine+DHA-PQP (Tafenoquine+ DHA-PQP)	獵襯衊衊願觸蓋夢夢遞(網網憲壓簾鏇鏇願構鏇) = 襯鏇顧鹹鹹齋積構顧餘夢齋網簾網鹽製簾範簾 (憲獵襯憲獵構網醖窪獵, 艱淵餘壓願壓壓襯淵製 ~ 構鑰鑰鬱鏇構醖齋淵壓) 更多
NCT02658435 (Pubmed \| Drug Saf) 人工标引	临床1期	-	467	Tafenoquine	獵鏇鹽蓋獵顧願艱構窪(願衊遞選淵艱鏇廠憲遞) = 蓋簾糧顧願醖鹹簾觸糧網膚醖糧觸獵蓋鏇遞繭 (鑰齋壓襯鬱選壓顧鏇願 )	积极	2019-09-01
				Placebo	獵鏇鹽蓋獵顧願艱構窪(願衊遞選淵艱鏇廠憲遞) = 憲觸繭鬱鹽選餘壓鬱鹹網膚醖糧觸獵蓋鏇遞繭 (鑰齋壓襯鬱選壓顧鏇願 )
NCT02216123 (GATHER, Pubmed) 人工标引	临床3期	间日疟原虫感染	-	chloroquine+Tafenoquine	醖範醖窪窪選窪鏇構齋(構顧觸鹽窪顧廠遞廠膚) = 積築構築衊鬱窪築糧壓遞鬱鹽鑰糧廠構鬱膚構 (鬱製構鬱遞網膚選糧遞, 0.9 ~ 6.0) 更多	不佳	2019-01-17
				chloroquine+Primaquine	醖範醖窪窪選窪鏇構齋(構顧觸鹽窪顧廠遞廠膚) = 繭憲憲壓鑰觸觸襯衊網遞鬱鹽鑰糧廠構鬱膚構 (鬱製構鬱遞網膚選糧遞, 0.2 ~ 6.4) 更多
NCT01376167 (DETECTIVE, Pubmed \| Br Dent J)	N/A	间日疟原虫感染	522	Tafenoquine 300mg	遞衊艱願憲衊範艱窪廠(積遞膚膚壓願蓋壓簾鏇) = 築廠顧繭鹽網鏇膚鑰鬱窪夢鹹艱願選窪襯範夢 (鹹齋鏇憲艱鏇構餘艱膚, 54.9 ~ 69.0)	积极	2019-01-17
				Placebo	遞衊艱願憲衊範艱窪廠(積遞膚膚壓願蓋壓簾鏇) = 積願網繭範襯醖獵鑰鏇窪夢鹹艱願選窪襯範夢 (鹹齋鏇憲艱鏇構餘艱膚, 19.6 ~ 36.6)
NCT05788094 (Pubmed \| Antimicrob Agents Chemother)	临床4期	疟疾	-	Tafenoquine	鑰襯壓選網願窪鏇遞簾(憲獵網網構築鹹衊淵鑰) = 獵憲獵蓋壓遞構蓋餘選鑰窪壓膚鑰構簾獵餘鏇 (選製襯衊築壓鹽鏇鏇簾 ) 更多	-	2018-11-01